It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

To determine whether increased androgen receptor protein concentration has a causal role in the hormone sensitive-to-hormone refractory ... LNCaP human prostate cancer cells.

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

SunRISe-5 and MoonRISe-1 trials investigate TAR-200 and TAR-210 in non-muscle-invasive bladder cancer, focusing on disease-free survival and recurrence prevention. ARASTEP trial evaluates darolutamide ...

A global research team has discovered a breakthrough set of urine biomarkers for prostate cancer that outperform the ...

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, ...

Prostate cancer has distinct genetic properties in different groups of men that could be targeted to improve patient outcomes, new research suggests.

Furthermore, in metastasis, cancer cells break away from the original tumor and travel through the blood or lymph system to form new tumors in other organs or tissues. These new tumors are made up of ...

Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered.